Phase I Study With an Immunomodulated Autologous Cell Vaccine for Locally Advanced Prostate Cancer

Berger, Milton; Horst, Jorge Luiz; Kreutz, Fernando; Pimentel, Maurício; Muller, Roberto L.; Koff, Walter José

doi:10.1016/s1569-9056(06)60300-x

Cited by 16 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These tumor cells are typically irradiated, combined with an immunostimulatory adjuvant (e.g., BCG), and then administered to the individual from whom the tumor cells were isolated (Berger et al, 2007; Harris et al, 2000; Maver and McKneally, 1979; Schulof et al, 1988). Autologous tumor cell vaccines have been tested in various cancers, including lung cancer (Nemunaitis, 2003; Ruttinger et al, 2007; Schulof et al, 1988), colorectal cancer (de Weger et al, 2012; Hanna et al, 2001; Harris et al, 2000; Ockert et al, 1996), melanoma (Baars et al, 2002; Berd et al, 1990; Mendez et al, 2007), renal cell cancer (Antonia et al, 2002; Fishman et al, 2008; Kinoshita et al, 2001) and prostate cancer (Berger et al, 2007). One major advantage of whole tumor cell vaccines is its potential to present the entire spectrum of tumor-associated antigens to the patient's immune system.…”

Section: Tumor Cell Vaccinesmentioning

confidence: 99%

Therapeutic Cancer Vaccines

Guo

Manjili

Subjeck

et al. 2013

Advances in Cancer Research

468

207

View full text Add to dashboard Cite

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim to treat late stage disease by using a patient's own immune system. The promising results from clinical trials recently led to the approval of the first therapeutic cancer vaccine by the U.S. Food and Drug Administration. This major breakthrough not only provides a new treatment modality for cancer management, but also paves the way for rationally designing and optimizing future vaccines with improved anticancer efficacy. Numerous vaccine strategies are currently being evaluated both pre-clinically and clinically. This review discusses therapeutic cancer vaccines of diverse platforms or targets as well as the preclinical and clinical studies employing these therapeutic vaccines. We will also consider tumor-induced immune suppression that hinders the potency of therapeutic vaccines, and potential strategies to counteract these mechanisms for generating more robust and durable antitumor immune responses.

show abstract

Section: Tumor Cell Vaccinesmentioning

confidence: 99%

Therapeutic Cancer Vaccines

Guo

Manjili

Subjeck

et al. 2013

Advances in Cancer Research

468

207

View full text Add to dashboard Cite

show abstract

“…Autologous cell vaccines have been tested on a variety of cancers, including lung, colorectal, melanoma, renal and prostate cancer [52][53][54][55][56]. Attenuated tumour cells have been administered to induce an immune response against specific types of cancers.…”

Section: Cellular Vaccinesmentioning

confidence: 99%

“…Two types of whole cell vaccines have been used: autologous and allogenic. Autologous cell vaccines have been tested on a variety of cancers, including lung, colorectal, melanoma, renal and prostate cancer [52][53][54][55][56]. However, autologous cell vaccines are limited to only certain types and stages of tumours, as they require a sufficient amount of the patient's tumour for preparation.…”

Section: Cellular Vaccinesmentioning

confidence: 99%

Novel approaches for the design, delivery and administration of vaccine technologies

Wallis

Shenton

Carlisle

2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary It is easy to argue that vaccine development represents humankind’s most important and successful endeavour, such is the impact that vaccination has had on human morbidity and mortality over the last 200 years. During this time the original method of Jenner and Pasteur, i.e. that of injecting live‐attenuated or inactivated pathogens, has been developed and supplemented with a wide range of alternative approaches which are now in clinical use or under development. These next‐generation technologies have been designed to produce a vaccine that has the effectiveness of the original live‐attenuated and inactivated vaccines, but without the associated risks and limitations. Indeed, the method of development has undoubtedly moved away from Pasteur’s three Is paradigm (isolate, inactivate, inject) towards an approach of rational design, made possible by improved knowledge of the pathogen–host interaction and the mechanisms of the immune system. These novel vaccines have explored methods for targeted delivery of antigenic material, as well as for the control of release profiles, so that dosing regimens can be matched to the time‐lines of immune system stimulation and the realities of health‐care delivery in dispersed populations. The methods by which vaccines are administered are also the subject of intense research in the hope that needle and syringe dosing, with all its associated issues regarding risk of injury, cross‐infection and patient compliance, can be replaced. This review provides a detailed overview of new vaccine vectors as well as information pertaining to the novel delivery platforms under development.

show abstract

“…4 The efficacy of such approach has been evaluated during the years in several clinical trials targeting different tumor types, including lung cancer, 5,6 colorectal cancer, [7][8][9] melanoma, [10][11][12] renal cell cancer 13,14 and prostate cancer. 15 However, sufficient amount of tumor specimen is needed for preparation of such autologous tumor cell vaccines, restraining its application to a limited number of tumor types or stages.…”

Section: Tumor Cell Vaccinesmentioning

confidence: 99%

Antigen-specific vaccines for cancer treatment

Tagliamonte

Petrizzo

Tornesello

et al. 2014

Human Vaccines & Immunotherapeutics

130

View full text Add to dashboard Cite

Vaccines targeting pathogens are generally effective and protective because based on foreign non-self antigens which are extremely potent in eliciting an immune response. On the contrary, efficacy of therapeutic cancer vaccines is still disappointing. One of the major reasons for such poor outcome, among others, is the difficulty of identifying tumor-specific target antigens which should be unique to the tumors or, at least, overexpressed on the tumors as compared to normal cells. Indeed, this is the only option to overcome the peripheral immune tolerance and elicit a non toxic immune response. New and more potent strategies are now available to identify specific tumor-associated antigens for development of cancer vaccine approaches aiming at eliciting targeted anti-tumor cellular responses. In the last years this aspect has been addressed and many therapeutic vaccination strategies based on either whole tumor cells or specific antigens have been and are being currently evaluated in clinical trials. This review summarizes the current state of cancer vaccines, mainly focusing on antigen-specific approaches.

show abstract

Phase I Study With an Immunomodulated Autologous Cell Vaccine for Locally Advanced Prostate Cancer

Cited by 16 publications

References 0 publications

Therapeutic Cancer Vaccines

Therapeutic Cancer Vaccines

Novel approaches for the design, delivery and administration of vaccine technologies

Antigen-specific vaccines for cancer treatment

Contact Info

Product

Resources

About